Loading...

TLX

TLX

TELIX PHARMACEUTICALS LTD

(TLX)

2026 6-K

Director Appointment

2 Apr '26

FDA Resubmission Update

16 Mar '26

Telix Study Results

10 Mar '26

Annual Report Filing

19 Feb '26

Marketing Authorization Sub...

18 Feb '26

New Drug Application

20 Jan '26

Telix Conference Announcement

12 Jan '26

Portfolio Update

22 Dec '25

Global Study Update

17 Dec '25

Patient Dosing Update

8 Dec '25

Financial Update

14 Oct '25

Announcement Summary

23 Sep '25

FDA Agreement Update

8 Sep '25

Regulatory Update

28 Aug '25

H1 2025 Results

20 Aug '25

Q2 Revenue Growth

22 Jul '25

Gozellix Code Approval

9 Jul '25

Investor Day Announcement

11 Jun '25

AGM Results 2025

21 May '25

Regulatory Update

28 Apr '25

Quarterly Earnings Report

22 Apr '25

AGM Notice Filed

17 Apr '25

Efficacy Update

17 Apr '25

Government Response

7 Apr '25

Director Appointment

3 Apr '25

FDA Approval Announcement

20 Mar '25

New Approval

18 Mar '25

Theranostic Acquisition

12 Mar '25

Share Sale Announcement

26 Feb '25

FDA Priority Review

26 Feb '25

Board Renewal Update

25 Feb '25

Currency Change

24 Feb '25

Financial Report Filing

21 Feb '25

UK Approval Announced

13 Feb '25

Asset Acquisition

31 Jan '25

Acquisition Completed

27 Jan '25

European Approval Received

16 Jan '25

Revenue Update

13 Jan '25

Acquisition Announcement

13 Jan '25

Regulatory Filing

30 Dec '24

Pipeline Expansion

19 Nov '24

Nasdaq Trading Start

14 Nov '24

External Links:

SEC

On March 10, 2026, Telix Pharmaceuticals announced that its ProstACT Global Phase 3 Study (Part 1) achieved its primary objectives and shared presentations about these results. This filing includes important developments previously reported to the Australian Securities Exchange.

AI Assistant

TELIX PHARMACEUTICALS LTD

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.